PTK2 and cancer: One of them called defactinib (also known as VS-6063 or PF-04554878), with high selectivity to PYK2 and FAK1 and low affinity to kinases outside the family35, has been successfully used to tackle cancer in a mouse model and is currently being tested in clinical trials36,37.